View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Christian Arnold ... (+2)
  • Christian Arnold
  • Tobias Fahrenholz

ODDO : Swiss Equities Conference Feedback – Difficult Q2 but some H2 2...

ODDO BHF and Commerzbank jointly hosted the Swiss Equities Conference in Interlaken, Switzerland, from 10 to 12 June 2025. The event was attended by 64 companies (out of which 59 are listed, and with BASF one non-Swiss company). Some 125 investors met mostly (85%) C-level management in 440 meetings (one-on-one, one-to-few) and plenary sessions, resulting in some 1,100 interactions. Based on our positive assessments for Q2 & H2 2025 as well as beyond, we would like to highlight Accelleron (poten...

Lonza Group AG: 1 director

A director at Lonza Group AG bought 100 shares at 563.068CHF and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Lonza - Biggest Tariff Beneficiary (BUY, TP CHF680 [650], 8pgs)

We believe Lonza is the biggest beneficiary of tariff fears under our coverage . TP to up CHF680 For access to the full note, please contact Naresh Chouhan ( )

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Merck KGaA - INITIATION - Springing to Life (BUY, TP EUR150, 54pgs)

We initiate with a BUY as we show why the SpringWorks deal transforms the outlook for Merck KGaA. We show it could be 17% accretive to group EPS by 2030, driven by our ~50% above consensus sales for Gomekli & Ogsiveo and we assume significant synergies. Moreover, we show that Healthcare sales now grow 5% CAGR to 2030 & EBITDA grows 8%. This is highly likely to drive a re-rating in the Merck KGaA shares in our view. There is upside potential from label expansions. Our view on the Life Science too...

Oliver Metzger
  • Oliver Metzger
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch